Mar 16, 2020   SOURCE: PR NewsWire

Bruton's Tyrosine Kinase (BTK) Inhibitors: Competitive Landscape, Global Markets and Pipeline Analysis (2020-2030)

DUBLIN, March 16, 2020 /PRNewswire/ -- The "Bruton's Tyrosine Kinase (BTK) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This report provides comprehensive insights on the therapeutic development for this mechanism of action. The objective of the report is to establish an understanding of the therapeutic competitive landscape for Bruton's Tyrosine Kinase (BTK) Inhibitors, including the marketed and pipeline products in this space.

The report provides detailed information on marketed products with historical and forecasted sales till 2030. It further offers comparative pipeline analysis with their drug profiles at various stages of development covering Phase III, Phase II, Phase I, Preclinical and Discovery. Information on company collaborations, agreements, acquisitions, licensing, deals, and other development activities is also involved in this report.

Therapeutics assessment of active pipeline drugs by stage, therapy type, route of administration, and molecule type is also covered in this report. It features the inactive pipeline products and highlights currently undergoing institutional research in this area. The report provides the understanding of the unmet needs, market drivers and barriers of the Bruton's Tyrosine Kinase Inhibitors market.

Future competitive landscape of Bruton's Tyrosine Kinase (BTK) Inhibitors is estimated to be very strong. Key emerging drugs including Principia Biopharma' PNR-1008 and others are going to be Blockbuster in the upcoming years.

This report on Bruton's Tyrosine Kinase (BTK) Inhibitors help companies in understanding market dynamics based on this mechanism of action and therefore giving opportunities for a strategic alliance that will result in market penetration and enhancement of portfolios with optimal investment and maximal return. In addition s will assuage companies to detect conditions, determine genetic predisposition and biological response to Bruton's Tyrosine Kinase (BTK) Inhibitors.

The report provides insights into:

    --  Detailed market drug profiles available in the market indicated for this
        mechanism of action with historical and forecasted sales till 2030.
    --  A number of companies developing therapies of Bruton's Tyrosine Kinase
        (BTK) Inhibitors with aggregate therapies developed by each company for
        the same.
    --  Detailed profiles of therapeutic candidates in nonclinical stage,
        early-stage, mid-stage and late-stage of development for Bruton's
        Tyrosine Kinase (BTK) Inhibitors.
    --  Analyses key players involved in Bruton's Tyrosine Kinase (BTK)
        Inhibitors targeted therapeutics development with respective active and
        inactive (dormant or discontinued) projects.
    --  Active pipeline therapies assessment under development based on the
        stage of development, route of administration, target receptor,
        monotherapy or combination therapy, a different mechanism of action, and
        molecular type.
    --  Detail analysis of collaboration (company-company collaborations and
        company-academia collaborations), licensing agreement and financing
        details for future developments of Bruton's Tyrosine Kinase (BTK)
        Inhibitors.

Scope of the Report

    --  The Bruton's Tyrosine Kinase Inhibitors report provides an overview of
        this mechanism of action, role, significance, pathway, types, and
        clinical application of IDH inhibitors.
    --  Therapeutic Assessment: Therapeutic pipeline activity and assessment of
        the products by development stage, product type, route of
        administration, molecule type, and MOA the complete product development
        cycle, including all clinical and nonclinical stages.
    --  It comprises of detailed profiles of therapeutic products for Bruton's
        Tyrosine Kinase (BTK) Inhibitors with key coverage of developmental
        activities, including collaborations, agreements, licensing, mergers and
        acquisition, funding, designations, technology and other product-related
        details.
    --  In-depth Bruton's Tyrosine Kinase Inhibitors research and development
        progress and trial details results wherever available, are also included
        in the pipeline study.
    --  Coverage of dormant and discontinued pipeline projects along with the
        reasons if available across Bruton's Tyrosine Kinase (BTK) Inhibitors.
    --  The report has also covered the worldwide market of Bruton's Tyrosine
        Kinase (BTK) Inhibitors, information of marketed therapies, their
        historical and forecasted sales till 2030.
    --  It also includes patent expiry details impact on market after expiry.
    --  Key topics covered include strategic competitor assessment, market
        characterization, opportunities, unmet needs, market growth factors,
        barriers and challenges along with SWOT analysis of the Bruton's
        Tyrosine Kinase Inhibitors market.
    --  Analysis of the current and future market competition in the global
        Bruton's Tyrosine Kinase Inhibitors market. Current scenario of the
        market with upcoming blockbuster molecules and their impact on the
        overall market.

Report Highlights

    --  In the coming years, the Bruton's Tyrosine Kinase Inhibitors market is
        set to change due to the extensive research in this filed, and
        incremental healthcare spending across the world; which would expand the
        size of the market to enable the drug manufacturers to penetrate more
        into the market.
    --  The companies and academics are working to assess challenges and seek
        opportunities that could influence Bruton's Tyrosine Kinase Inhibitors
        R&D. The Bruton's Tyrosine Kinase Inhibitors therapies under development
        are focused on novel approaches to treat/improve the disease condition.
    --  There are many companies involved in developing therapies for Bruton's
        Tyrosine Kinase (BTK) Inhibitors. Launch of emerging therapies of
        Bruton's Tyrosine Kinase (BTK) Inhibitors will significantly impact the
        market.
    --  A better understanding of the target mechanism will also contribute to
        the development of novel therapeutics for Bruton's Tyrosine Kinase (BTK)
        Inhibitors.
    --  Our in-depth analysis of the pipeline assets (in early-stage, mid-stage
        and late-stage of development for the treatment of Bruton's Tyrosine
        Kinase (BTK) Inhibitors includes therapeutic assessment and comparative
        analysis. This will support the clients in the decision-making process
        regarding their therapeutic portfolio by identifying the overall
        scenario of the research and development activities.
    --  The report provides the detailed analysis of 30+ products along with 25+
        companies involved.

Key Questions Answered

    --  What are Bruton's Tyrosine Kinase (BTK) Inhibitors, their role and
        significance in the treatment of disease conditions?
    --  What are the current treatment options based on the Bruton's Tyrosine
        Kinase (BTK) Inhibitors available in the market?
    --  How the historical and forecasted sales of the marketed therapies
        determine their scenario in the current Bruton's Tyrosine Kinase
        Inhibitors market?
    --  How many therapies are developed by each company for Bruton's Tyrosine
        Kinase (BTK) Inhibitors to treat disease conditions?
    --  What are the key collaborations (Industry-Industry, Industry-Academia),
        mergers and acquisitions, licensing activities related to the Bruton's
        Tyrosine Kinase Inhibitors therapies?
    --  Which are the dormant and discontinued products and the reasons for
        dormancy and discontinuation?
    --  What is the unmet need for current therapies developed on the basis of
        this mechanism of action?
    --  What are the recent novel therapies, targets, mechanisms of action and
        technologies developed to overcome the limitation of existing therapies?
    --  What are the clinical studies going on for Bruton's Tyrosine Kinase
        (BTK) Inhibitors and their status?

Companies Mentioned

    --  BeiGene
    --  Merck
    --  Principia Biopharma
    --  ACEA Biosciences
    --  Bristol-Myers Squibb
    --  AbbVie
    --  Celgene Corporation
    --  Ono Pharmaceutical
    --  Roche
    --  Novartis
    --  and many more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9npn83

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/brutons-tyrosine-kinase-btk-inhibitors-competitive-landscape-global-markets-and-pipeline-analysis-2020-2030-301024758.html

SOURCE Research and Markets